Guanfacin (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Guanfacin" in German language version.

refsWebsite
Global rank German rank
4th place
7th place
2nd place
3rd place
low place
6,408th place
low place
1,805th place
68th place
29th place
low place
low place
1,538th place
2,879th place
399th place
3,700th place
low place
low place

apotheke-adhoc.de

cmocro.com

doi.org

  • N. T. Bello: Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents. In: Patient preference and adherence. Band 9, 2015, S. 877–885. doi:10.2147/PPA.S73167. PMID 26170637, PMC 4494608 (freier Volltext) (Review).
  • Akira Iwanami, Kazuhiko Saito, Masakazu Fujiwara, Daiki Okutsu, Hironobu Ichikawa: Efficacy and Safety of Guanfacine Extended-Release in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study. In: The Journal of Clinical Psychiatry. Band 81, Nr. 3, 14. April 2020, S. 19m12979, doi:10.4088/JCP.19m12979, PMID 32297719.
  • Bernard J. Lee: Clinical experience with guanfacine in 2- and 3-year-old children with Attention Deficit Hyperactivity Disorder. In: Infant Mental Health Journal. Band 18, Nr. 3, September 1997, S. 300–305, doi:10.1002/(SICI)1097-0355(199723)18:33.0.CO;2-Q.
  • Amy FT Arnsten: The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder. In: Expert Review of Neurotherapeutics. Nr. 10, Oktober 2010, S. 1595–1605, doi:10.1586/ern.10.133, PMC 3143019 (freier Volltext).
  • X.-P. Huang, V. Setola, P. N. Yadav, J. A. Allen, S. C. Rogan, B. J. Hanson, C. Revankar, M. Robers, C. Doucette, B. L. Roth: Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment. In: Molecular Pharmacology. 76, 2009, S. 710. doi:10.1124/mol.109.058057. PMC 2769050 (freier Volltext).
  • Elena Cichero, Valeria Francesconi, Beatrice Casini, Monica Casale, Evgeny Kanov, Andrey S. Gerasimov, Ilya Sukhanov, Artem Savchenko, Stefano Espinoza, Raul R. Gainetdinov, Michele Tonelli: Discovery of Guanfacine as a Novel TAAR1 Agonist: A Combination Strategy through Molecular Modeling Studies and Biological Assays. In: Pharmaceuticals. Band 16, Nr. 11, 20. November 2023, S. 1632, doi:10.3390/ph16111632, PMID 38004497, PMC 10674299 (freier Volltext).
  • B. P. Ramos, D. Stark, L. Verduzco, C. H. van Dyck, A. F. Arnsten: Alpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals. In: Learning & memory. Band 13, Nummer 6, Nov-Dez 2006, S. 770–776. doi:10.1101/lm.298006. PMID 17101879, PMC 1783631 (freier Volltext).
  • A. B. Fernando, D. Economidou, D. E. Theobald, M. F. Zou, A. H. Newman, M. Spoelder, D. Caprioli, M. Moreno, L. Hipólito, A. T. Aspinall, T. W. Robbins, J. W. Dalley: Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonists. In: Psychopharmacology. Band 219, Nummer 2, Januar 2012, S. 341–352. doi:10.1007/s00213-011-2408-z. PMID 21761147, PMC 3249163 (freier Volltext).

drugs.com

europa.eu

ema.europa.eu

kompendium-news.de

nih.gov

ncbi.nlm.nih.gov

  • N. T. Bello: Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents. In: Patient preference and adherence. Band 9, 2015, S. 877–885. doi:10.2147/PPA.S73167. PMID 26170637, PMC 4494608 (freier Volltext) (Review).
  • P. Jerie: Clinical experience with guanfacine in long-term treatment of hypertension. In: British journal of clinical pharmacology. Band 10, Suppl 1, 1980, S. 37S–47S. PMID 6994777, PMC 1430120 (freier Volltext).
  • Akira Iwanami, Kazuhiko Saito, Masakazu Fujiwara, Daiki Okutsu, Hironobu Ichikawa: Efficacy and Safety of Guanfacine Extended-Release in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study. In: The Journal of Clinical Psychiatry. Band 81, Nr. 3, 14. April 2020, S. 19m12979, doi:10.4088/JCP.19m12979, PMID 32297719.
  • Amy FT Arnsten: The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder. In: Expert Review of Neurotherapeutics. Nr. 10, Oktober 2010, S. 1595–1605, doi:10.1586/ern.10.133, PMC 3143019 (freier Volltext).
  • X.-P. Huang, V. Setola, P. N. Yadav, J. A. Allen, S. C. Rogan, B. J. Hanson, C. Revankar, M. Robers, C. Doucette, B. L. Roth: Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment. In: Molecular Pharmacology. 76, 2009, S. 710. doi:10.1124/mol.109.058057. PMC 2769050 (freier Volltext).
  • Elena Cichero, Valeria Francesconi, Beatrice Casini, Monica Casale, Evgeny Kanov, Andrey S. Gerasimov, Ilya Sukhanov, Artem Savchenko, Stefano Espinoza, Raul R. Gainetdinov, Michele Tonelli: Discovery of Guanfacine as a Novel TAAR1 Agonist: A Combination Strategy through Molecular Modeling Studies and Biological Assays. In: Pharmaceuticals. Band 16, Nr. 11, 20. November 2023, S. 1632, doi:10.3390/ph16111632, PMID 38004497, PMC 10674299 (freier Volltext).
  • B. P. Ramos, D. Stark, L. Verduzco, C. H. van Dyck, A. F. Arnsten: Alpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals. In: Learning & memory. Band 13, Nummer 6, Nov-Dez 2006, S. 770–776. doi:10.1101/lm.298006. PMID 17101879, PMC 1783631 (freier Volltext).
  • A. B. Fernando, D. Economidou, D. E. Theobald, M. F. Zou, A. H. Newman, M. Spoelder, D. Caprioli, M. Moreno, L. Hipólito, A. T. Aspinall, T. W. Robbins, J. W. Dalley: Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonists. In: Psychopharmacology. Band 219, Nummer 2, Januar 2012, S. 341–352. doi:10.1007/s00213-011-2408-z. PMID 21761147, PMC 3249163 (freier Volltext).
  • J. R. Kiechel: Pharmacokinetics and metabolism of guanfacine in man: a review. In: British journal of clinical pharmacology. Band 10, Suppl 1, 1980, S. 25S–32S. PMID 6994775, PMC 1430131 (freier Volltext).
  • G. Scholtysik: Inhibition of effects of accelerator nerve stimulation in cats and rabbits by BS 100-141 and guanabenz. In: Naunyn Schmiedebergs Arch. Pharmacol. Band 282, (Suppl), 1974, S. R86. PMID 4276642

tcichemicals.com

unc.edu

pdsp.unc.edu

  • B. L. Roth, J. Driscol: PDSP Ki Database. University of North Carolina at Chapel Hill and the United States National Institute of Mental Health.